Story
UK Grants First European Approval for Eli Lilly's Oral Weight-Loss Pill Orforglipron

The United Kingdom has become the first country in Europe to approve Eli Lilly's (NYSE: LLY) oral drug orforglipron for weight management and the treatment of type 2 diabetes. The Medicines and Healthcare products Regulatory Agency (MHRA) announced its authorization on Monday, clearing the path for the new treatment in the UK market.
Regulatory Green Light
The MHRA's decision permits the use of orforglipron, which will be marketed under the brand name Foundayo, for two key indications. According to the agency, the approval covers its use as a treatment for adults with type 2 diabetes and for weight management, including weight loss and weight maintenance.
This authorization is a significant milestone, establishing a new treatment option within the rapidly growing class of drugs known as GLP-1 receptor agonists. Unlike many popular existing treatments in this class that require injections, orforglipron is a once-daily tablet.
AdMarket Implications
The approval positions Eli Lilly to compete more directly in the oral segment of the multi-billion dollar market for obesity and diabetes drugs, which is currently dominated by Novo Nordisk's injectable products Ozempic and Wegovy, and its oral tablet Rybelsus. The convenience of a daily pill could be a key differentiator for patients and physicians.
For investors, this development strengthens Eli Lilly's portfolio in a highly lucrative therapeutic area. The company already markets the successful injectable GLP-1/GIP agonist Zepbound (tirzepatide) for weight loss. The addition of an effective oral option like orforglipron could significantly expand its market share and patient reach, pending pricing and availability details.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.